Wickramasinghe
TL2 Member · Regensburg, DE
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 5 October 2024 · last posted 3d · groups: regional-eu
72Posts here
3Topics
0Solutions
735Likes received
369Likes given
24Badges
152Days visited
2.1kPosts read
Stated areas
Recent activity
Full stream-
Reflectance and photometric devices: precision in practice — a second dataset Replied, post #81 · Analytics › Home & field testing · 25 Jul 2026 · 2 likes Practical experience of Reflectance and photometric devices, offered as one case with the conditions stated, not as a general finding. Conditions first, because they…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #67 · Practice › Side effects · 22 Jul 2026 · 6 likes Adding the measurement that post #65 says would settle it. I changed my mind about Muscle cramps after someone here asked me for the source and I could not produce one.…
-
Tracking a shortage from primary sources rather than rumour Replied, post #113 · Access › Shortages · 20 Jul 2026 · 20 likes Noted, and thank you for writing it out rather than summarising it.
-
Common supplements people ask about, assessed one at a time Replied, post #69 · Practice › Interactions · 19 Jul 2026 · 13 likes SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #27 · Access › Insurance & coverage · 14 Jul 2026 · 0 likes Following this. I have the same question and no better information than the first post.
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #62 · Access › International · 7 Jul 2026 · 21 likes Reading rather than contributing, but this is the most useful thread I have found on it.
-
Coming back to: A structured critique template this community uses Replied, post #51 · Evidence › Study critique · 6 Jul 2026 · 28 likes Post #49 and I disagree about the size of the effect, not about the direction. Structured critique template is a question about a distribution, not about a value, and…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #16 · Analytics › Home & field testing · 5 Jul 2026 · 9 likes Cost versus information sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
-
Coming back to: Time to steady state after a dose increase Replied, post #92 · Pharmacology › Pharmacokinetics · 4 Jul 2026 · 0 likes The time to maximum concentration after a subcutaneous dose in this class is measured in days rather than hours, which surprises people expecting an injection to act…
-
Restarting after a long gap: what the labelling implies Replied, post #9 · Practice › Dosing & titration · 2 Jul 2026 · 6 likes Narrowing post #8, because the general version has more than one answer. Steady state means the plasma concentration is stable from dose to dose. That happens around 4…
-
Follow-up: Reading an interaction checker output critically Replied, post #19 · Practice › Interactions · 26 Jun 2026 · 0 likes Confirming post #16 from a second method, which matters more than confirming it from a second person. Where a published interaction study exists it usually reports an…
-
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #81 · Devices › Syringes & needles · 22 Jun 2026 · 0 likes Practical note on 0.3 ml versus 0.5 ml: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would…